Takata, Keiko
Nakazawa, Masami
Honda, Keiichi
Hashimoto, Sayo
Article History
Received: 29 September 2021
Accepted: 31 December 2021
First Online: 19 January 2022
Declarations
:
: This surveillance was conducted in accordance with the Declaration of Helsinki. The post-marketing drug-use surveillance was conducted in compliance with Good Post-marketing Study Practice according to ordinance by the Japanese Ministry of Health, Labour, and Welfare. According to exemptions under the Good Post-Marketing Study Practice ordinance by the Ministry of Health, Labour, and Welfare, institutional review board approval and informed consent are not required in Japan.
: Not applicable.
: Not applicable.
: KT, MN, and KH are employees of Shionogi Pharmacovigilance Center Co., Ltd. SH is employees of Shionogi & Co., Ltd.